ALUNBRIG.02
Ligne de thérapie ultérieure (avec modèle de prix)
Après accord sur la prise en charge …
Additional information from the official database
| Substance | Quantity | Type | Category |
|---|---|---|---|
|
I
|
90.0 MG | Substance | Wirkstoff (Principe actif) |
|
II
|
180.0 MG | Substance | Wirkstoff (Principe actif) |
|
II
|
336.33 MG | Substance | HBESI |
|
I
|
168.17 MG | Substance | HBESI |
|
I
|
- | Substance | HNIDK |
|
II
|
- | Substance | HNIDK |
|
II
|
- | Substance | HNIDK |
|
I
|
- | Substance | HNIDK |
|
I
|
- | Substance | HBESI |
|
II
|
- | Substance | HBESI |
|
I
|
- | Substance | HNIDK |
|
II
|
- | Substance | HNIDK |
|
I
|
- | Substance | HNIDK |
|
II
|
- | Substance | HNIDK |
|
I
|
- | Substance | HNIDK |
|
II
|
- | Substance | HNIDK |
|
II
|
- | Substance | HNIDK |
|
I
|
- | Substance | HNIDK |
|
II
|
- | Substance | HNIDK |
|
I
|
- | Substance | HNIDK |
|
II
|
- | Substance | FNIDK |
|
I
|
- | Substance | FNIDK |
8152 Opfikon